Platform | Publications

Delivering on the RNA Revolution

Antibody Oligonucleotide Conjugates (AOC) therapeutics are designed to combine the proven technology of monoclonal antibodies (mAbs) with the precision and potency of oligonucleotide therapies to access previously untreatable tissue and cell types, opening new potential treatments for patients. We have done the experiments and have followed the data to build our AOC platform. We are revolutionizing the RNA therapeutics field by delivering oligonucleotides where they are needed – including beyond the liver.

Publications

May 24, 2023

Targeted Tissue Delivery of RNA Therapeutics Using Antibody–Oligonucleotide Conjugates (AOCs)

Nucleic Acids Research
Barbora Malecova, Rob S Burke, Michael Cochran, Michael D Hood, Rachel Johns, Philip R Kovach, Venkata R Doppalapudi, Gulin Erdogan, J Danny Arias, Beatrice Darimont, Christopher D Miller, Hanhua Huang, Andrew Geall, Husam S Younis, Arthur A Levin. Nucleic Acids Research, 2023;, gkad415, https://doi.org/10.1093/nar/gkad415

January 5, 2017

Targeting Therapeutic Oligonucleotides

The New England Journal of Medicine
Levin, AA. N Engl J Med 2017;376:1DOI 10.1056/NEJMcibr1613559

January 5, 2017

Treating Disease at the RNA Level with Oligonucleotides

The New England Journal of Medicine
Levin, AA. N Engl J Med 2019;380:1DOI: 10.1056/NEJMra1705346

Presentations

2023 NMSG 24TH ANNUAL SCIENTIFIC MEETING

Phase 1/2 Trial Evaluating AOC 1044 in Healthy Volunteers and Participants with DMD Mutations Amenable to Exon 44 Skipping (DMD44): EXPLORE44™️ Trial Design

Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of AOC 1020 Administered Intravenously to Adult Patients with Facioscapulohumeral Muscular Dystrophy (FORTITUDE™️) Trial Design

2023 Myotonic Dystrophy Foundation Annual Conference

From Myotube to Patient: AOC 1001 Demonstrates DMPK Reduction and Spliceopathy Improvement in a Phase 1/2 Study in Myotonic Dystrophy Type 1 (DM1) (MARINA™️️️)

Topline Data Analysis of the Phase 1/2 Clinical Trial Evaluating AOC 1001 in Adult Patients with Myotonic Dystrophy Type 1: MARINA™️️️

2023 FSHD Society International Research Congress

Facioscapulohumeral Muscular Dystrophy (FSHD) Surgeries, Cardiovascular Testing, Mobility Aids and Healthcare Utilization After Diagnosis from a Real-World Data Analysis

Phase 1/2 Trial Evaluating AOC 1020 in Adults with FSHD: FORTITUDE Trial Design

AOC 1020: An Antibody Oligonucleotide Conjugate (AOC) in Development for the Treatment of FSHD

Facioscapulohumeral Muscular Dystrophy (FSHD) Age-related Differences in Symptoms Among Patients Over and Under 40-Years

2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference

Comparative Real‐World Retrospective Data Analysis of Comorbid Conditions and Healthcare Utilization for Patients with Myotonic Dystrophy Over a 5‐Year Timeframe

2023 75th AAN Annual Meeting

Preliminary Assessment of the Phase 1/2 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Patients with Myotonic Dystrophy Type 1 (DM1) (MARINA)

Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of AOC 1020 Administered Intravenously to Adult Patients with Facioscapulohumeral Muscular Dystrophy (FORTITUDE) Trial Design

2023 MDA Clinical and Scientific Conference

Phase 1/2 Clinical Trial Evaluating the Safety and Pharmacokinetics of AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA Trial in Progress

AOC 1020: An Antibody Oligonucleotide Conjugate (AOC) in Development for the Treatment of FSHD

Myotonic Dystrophy, Comorbid Conditions and Healthcare Utilization Based on a 5-Year Comparative Real-World Data Analysis

AOC 1044: An Antibody Oligonucleotide Conjugate as a Novel Therapeutic Approach for DMD Patients Amenable to Exon 44 Skipping

Burden of Duchenne Muscular Dystrophy in Patients with Mutations Amenable to Exon 44 Skipping (DMD44)

Phase 1/2 Trial Evaluating AOC 1020 Safety and Pharmacokinetics in Adults with Facioscapulohumeral Muscular Dystrophy (FSHD): FORTITUDE Trial Design

2023 AMCP Annual Meeting

Specialty Pharmacy Products Used by Patients with Myotonic Dystrophy 2-Years Pre- and Post-Diagnosis

Prescription Medication Use Prior to and Following a Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): Learnings from the Patient Journey

2022 World Muscle Society Congress

A Phase 1/2 Clinical Trial Evaluating the Safety and Pharmacokinetics of AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA Study Design

AOC 1020: An Antibody Oligonucleotide Conjugate (AOC) in Development for the Treatment of FSHD

Durable AOC Mediated Exon 44 Skipping In Non-Human Primate Muscle Tissue And Dystrophin Protein Restoration In DMD Patient Derived Skeletal Muscle Cells

Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM) Pre- and Post-Diagnosis: A Real-World Data Analysis

Understanding the Patients’ Journey Pre- and Post-Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): A Real-World Retrospective Data Analysis

2022 FSHD Society International Research Congress

AOC 1020: An Antibody Oligonucleotide Conjugate (AOC) in Development for the Treatment of FSHD

Inpatient Admissions and Emergency Department Visits for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD): A Real-World Retrospective Data Analysis of Pre- and Post-Diagnosis Events

2022 74th AAN Annual Meeting

Study Design of AOC 1001-CS1, a Phase 1/2 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Patients with Myotonic Dystrophy Type 1 (DM1) (MARINA™)

Antibody-Oligonucleotide Conjugates (AOCs) Demonstrate Potent and Durable Exon Skipping and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy

Prevalence of healthcare conditions and services used by patients with myotonic dystrophy (DM1 and DM2) prior to diagnosis; a real-world data analysis

Understanding the patients’ journey to the diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a real-world retrospective data analysis

DUX4 siRNA Optimization for the Development of an Antibody-Oligonucleotide Conjugate (AOC™) for the Treatment of FSHD

2022 MDA Clinical and Scientific Conference

DUX4 siRNA Optimization for the Development of an Antibody-Oligonucleotide Conjugate (AOC^TM) for the Treatment of FSHD

A Phase 1/2 Clinical Trial Evaluating the Safety and Pharmacokinetics of AOC 1001 in Adults with Myotonic Dystrophy Type 1 (DM1): MARINA Study Design

Understanding the patients’ journey pre- and post-diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a real-world retrospective data analysis

Prevalence of healthcare conditions and services used by patients with myotonic dystrophy pre-and post-diagnosis, a real-world data analysis

2021 MDA Virtual Clinical and Scientific Conference

DUX4 siRNA Optimization for the Development of an Antibody-Oligonucleotide Conjugate (AOC^™) for the Treatment of FSHD

2021 AAN Annual Meeting

Optimization of AOC 1001, an antibody-oligonucleotide conjugate targeting the underlying cause of myotonic dystrophy type 1

2021 FSHD Society IRC Annual Meeting

DUX4 siRNA Optimization for the Development of an Antibody Oligonucleotide Conjugate (AOC^™) for the Treatment of FSHD